| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
752.85(B) |
| Last
Volume: |
3,037,186 |
Avg
Vol: |
3,290,337 |
| 52
Week Range: |
$423.21 - $792.28 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
220,750 |
870,750 |
2,710,260 |
6,211,418 |
| Total Sell Value |
$171,350,547 |
$608,250,580 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
2 |
2 |
5 |
6 |
| Total Sell Transactions |
3 |
13 |
42 |
89 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lilly Endowment Inc |
10% Owner |
– – • |
2022-06-27 |
4 |
S |
$329.05 |
$13,772,837 |
D/D |
(41,857) |
104,161,953 |
|
-9% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-06-24 |
4 |
S |
$321.98 |
$69,726,324 |
D/D |
(215,000) |
104,203,810 |
|
-11% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-06-23 |
4 |
S |
$309.23 |
$63,764,750 |
D/D |
(205,000) |
104,418,810 |
|
-14% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-06-22 |
4 |
S |
$305.62 |
$64,435,611 |
D/D |
(210,000) |
104,623,810 |
|
-15% |
|
| Fyrwald J Erik |
Director |
– • – |
2022-06-21 |
4 |
A |
$297.34 |
$9,812 |
D/D |
33 |
69,497 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2022-06-21 |
4 |
A |
$297.34 |
$9,812 |
D/D |
33 |
51 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2022-06-21 |
4 |
A |
$297.34 |
$11,299 |
D/D |
38 |
51,700 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2022-06-21 |
4 |
A |
$297.34 |
$13,975 |
D/D |
47 |
13,865 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2022-06-21 |
4 |
A |
$297.34 |
$9,812 |
D/D |
33 |
900 |
|
- |
|
| Johnson Kimberly H |
Director |
– • – |
2022-06-21 |
4 |
A |
$297.34 |
$9,812 |
D/D |
33 |
1,271 |
|
- |
|
| Zakrowski Donald A |
Chief Accounting Officer |
• – – |
2022-06-01 |
4 |
AS |
$313.44 |
$313,440 |
D/D |
(1,000) |
6,274 |
|
5% |
|
| Rau Diogo |
SVP & CIDO |
• – – |
2022-06-01 |
4 |
D |
$313.44 |
$992,351 |
D/D |
(3,166) |
4,394 |
|
- |
|
| Rau Diogo |
SVP & CIDO |
• – – |
2022-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,560 |
7,560 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-05-27 |
4 |
S |
$314.44 |
$63,796,661 |
D/D |
(200,000) |
104,833,810 |
|
-1% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-05-26 |
4 |
S |
$308.52 |
$55,526,821 |
D/D |
(178,390) |
105,033,810 |
|
-6% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-05-25 |
4 |
S |
$308.30 |
$12,855,267 |
D/D |
(41,610) |
105,212,200 |
|
-8% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-05-24 |
4 |
S |
$305.74 |
$30,597,961 |
D/D |
(100,000) |
105,253,810 |
|
-8% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-05-23 |
4 |
S |
$302.34 |
$35,981,664 |
D/D |
(118,856) |
105,353,810 |
|
-6% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-05-18 |
4 |
S |
$302.00 |
$211,400 |
D/D |
(700) |
105,472,666 |
|
-13% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2022-05-17 |
4 |
S |
$302.24 |
$5,949,343 |
D/D |
(19,683) |
105,473,366 |
|
-3% |
|
| Greene Gabrielle E |
Director |
– • – |
2022-05-16 |
4 |
A |
$299.38 |
$9,880 |
D/D |
33 |
864 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2022-05-16 |
4 |
A |
$299.38 |
$9,880 |
D/D |
33 |
69,236 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2022-05-16 |
4 |
A |
$299.38 |
$5,389 |
D/D |
18 |
18 |
|
- |
|
| Johnson Kimberly H |
Director |
– • – |
2022-05-16 |
4 |
A |
$299.38 |
$9,580 |
D/D |
32 |
1,234 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2022-05-16 |
4 |
A |
$299.38 |
$14,071 |
D/D |
47 |
13,773 |
|
- |
|
1437 Records found
|
|
Page 13 of 58 |
|
|
23.04 (3.02%) 
